Kymera Therapeutics (KYMR) Asset Writedowns and Impairment (2024 - 2025)
Kymera Therapeutics (KYMR) posted quarterly Asset Writedowns and Impairment of $45000.0 for Q4 2025, down 98.83% quarter-over-quarter from $3.9 million in Q3 2025.
Kymera Therapeutics (KYMR) Asset Writedowns and Impairment (2024 - 2025) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Asset Writedowns and Impairment for 2 consecutive years, with $45000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Asset Writedowns and Impairment changed N/A year-over-year to $45000.0; the TTM figure through Dec 2025 stood at $3.9 million (down 20.81% YoY), while the FY2025 annual figure was $3.9 million, down 20.81% from the prior year.
- Asset Writedowns and Impairment declined to $45000.0 in Q4 2025 per KYMR's latest filing, from $3.9 million in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $4.9 million in Q1 2024 and bottomed at $45000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 45,000.00 |
| Dec 31, 2025 | 45,000.00 |
| Sep 30, 2025 | 3.86 Mn |
| Sep 30, 2025 | 3.86 Mn |
| Mar 31, 2024 | 4.93 Mn |
| Mar 31, 2024 | 4.93 Mn |